TLR9 agonists induced cell death in Burkitt's lymphoma cells is variable and influenced by TLR9 polymorphism

Cell Death and Disease

Volumn 3, Issue 6, 2012, Pages

  Noack, J ^a   Jordi, M ^a   Zauner, L ^a   Alessi, D ^a   Burch, A ^a   Tinguely, M ^a   Hersberger, M ^a   Bernasconi, M ^a   Nadal, D ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Burkitt's lymphoma; CpG; Epstein Barr virus; polymorphism; Toll like receptor TLR 9 agonists

Indexed keywords

TOLL LIKE RECEPTOR 9; INTERLEUKIN 1 RECEPTOR; MEMBRANE PROTEIN; OLIGODEOXYRIBONUCLEOTIDE; TIRAP PROTEIN, HUMAN; TLR9 PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; INNATE IMMUNITY; LATENT VIRUS INFECTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; AGED; CELL DEATH; CPG ISLAND; DRUG EFFECT; DRUG POTENTIATION; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4;

ADULT; AGED; BURKITT LYMPHOMA; CELL DEATH; CPG ISLANDS; HERPESVIRUS 4, HUMAN; HUMANS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; POLYMORPHISM, GENETIC; RECEPTORS, INTERLEUKIN-1; TOLL-LIKE RECEPTOR 9;

EID: 84863475067     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.60     Document Type: Article

References (39)

1. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-995.
2. Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R, Jego G. Toll-like receptors: Lessons to learn from normal and malignant human B cells. Blood 2008; 112: 2205-2213.
3. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005; 204: 27-42.
4. Bourke E, Bosisio D, Golay J, Polentarutti N, Mantovani A. The toll-like receptor repertoire of human B lymphocytes: Inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 2003; 102: 956-963.
5. Dorner M, Brandt S, Tinguely M, Zucol F, Bourquin JP, Zauner L et al. Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology 2009; 128: 573-579.
6. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168: 4531-4537.
7. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009; 61: 195-204.
8. Weiner GJ. CpG oligodeoxynucleotide-based therapy of lymphoid malignancies. Adv Drug Deliv Rev 2009; 61: 263-267.
9. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008; 27: 161-167.
10. Liang X, Moseman EA, Farrar MA, Bachanova V, Weisdorf DJ, Blazar BR et al. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood 2010; 115: 5041-5052.
11. Jahrsdorfer B, Muhlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann E et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 2005; 11: 1490-1499.
12. Decker T, Schneller F, Sparwasser T, Tretter T, Lipford GB, Wagner H et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000; 95: 999-1006.
13. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005; 65: 5009-5014.
14. Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in carcinogenesis and anti-Tumor treatment. Cell Mol Biol Lett 2009; 14: 248-272.
15. Ladell K, Dorner M, Zauner L, Berger C, Zucol F, Bernasconi M et al. Immune activation suppresses initiation of lytic Epstein-Barr virus infection. Cell Microbiol 2007; 9: 2055-2069.
16. Zauner L, Melroe GT, Sigrist JA, Rechsteiner MP, Dorner M, Arnold M et al. TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification. Oncogene 2010; 29: 4588-4598.
17. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4: 757-768.
18. Rickinson A, Kieff E. Epstein-Barr virus. In: Knipe DM (ed) Fields Virology. 4th edn. Lippincott Williams & Wilkins: Philadelphia, PA, 2001; pp 2575-2627.
19. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR et al. An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. Nat Med 2004; 10: 871-875.
20. Carvalho A, Cunha C, Almeida AJ, Osorio NS, Saraiva M, Teixeira-Coelho M et al. The rs5743836 polymorphism in TLR9 confers a population-based increased risk of non- Hodgkin lymphoma. Genes Immun 2012; 13: 197-210.
21. Peng SL. Signaling in B cells via Toll-like receptors. Curr Opin Immunol 2005; 17: 230-236.
22. Jahrsdorfer B, Hartmann G, Racila E, Jackson W, Muhlenhoff L, Meinhardt G et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001; 69: 81-88.
23. Jenkins PJ, Binne UK, Farrell PJ. Histone acetylation and reactivation of Epstein-Barr virus from latency. J Virol 2000; 74: 710-720.
24. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin- 10 receptor. Annu Rev Immunol 2001; 19: 683-765.
25. Beatty PR, Krams SM, Martinez OM. Involvement of IL-10 in the autonomous growth of EBV-Transformed B cell lines. J Immunol 1997; 158: 4045-4051.
26. Jones KD, Aoki Y, Chang Y, Moore PS, Yarchoan R, Tosato G. Involvement of interleukin- 10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirusassociated infected primary effusion lymphoma cells. Blood 1999; 94: 2871-2879.
27. Ng MT, Van't Hof R, Crockett JC, Hope ME, Berry S, Thomson J et al. Increase in NF-kappaB binding affinity of the variant C allele of the toll-like receptor 9 -1237T/C polymorphism is associated with Helicobacter pylori-induced gastric disease. Infect Immun 2010; 78: 1345-1352.
28. Soriano-Sarabia N, Vallejo A, Ramirez-Lorca R, Rodriguez Mdel M, Salinas A Pulido I et al. Influence of the Toll-like receptor 9 1635A/G polymorphism on the CD4 count, HIV viral load, and clinical progression. JAIDS 2008; 49: 128-135.
29. Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu DH et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992; 89: 1890-1893.
30. Masood R, Zhang Y, Bond MW, Scadden DT, Moudgil T, Law RE et al. Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood 1995; 85: 3423-3430.
31. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010; 10: 170-181.
32. Latz E, Verma A, Visintin A, Gong M, Sirois CM, Klein DC et al. Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol 2007; 8: 772-779.
33. Grauer OM, Molling JW, Bennink E, Toonen LW, Sutmuller RP, Nierkens S et al. TLR ligands in the local treatment of established intracerebral murine gliomas. J Immunol 2008; 181: 6720-6729.
34. Castro JE, Prada CE, Aguillon RA, Kitada S, Fukuda T, Motta M et al. Thymidinephosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference. Leukemia 2006; 20: 680-688.
35. Sanjuan MA, Rao N, Lai KT, Gu Y, Sun S, Fuchs A et al. CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion. J Cell Biol 2006; 172: 1057-1068.
36. Ng MT, Van't Hof R, Crockett JC, Hope ME, Berry S, Thomson J et al. Increase in NFkappaB binding affinity of the variant C allele of the toll-like receptor 9 -1237T/C polymorphism is associated with Helicobacter pylori-induced gastric disease. Infect Immun 2010; 78: 1345-1352.
37. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, 2008.
38. Muntwyler J, Marti-Jaun J, Luscher TF, Hanseler E, Hersberger M. The Asp298 but not the C-786 genotype of the endothelial nitric oxide synthase is reduced with age in healthy Swiss men. Clin chem lab med: CCLM/FESCC 2005; 43: 971-973.
39. Krayenbuehl PA, Hersberger M, Truninger K, Mullhaupt B, Maly FE, Bargetzi M et al. Tolllike receptor 4 gene polymorphism modulates phenotypic expression in patients with hereditary hemochromatosis. Eur J Gastroenterol Hepato 2010; 22: 835-841.